HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS CONFERENCE CALENDAR
LATEST UPDATES » Vol 21, No 02, February 2017 – War on CANCER       » Two Scientists Share China's Top Science Award       » China Donates Mobile Clinics to Kenya       » Cervical Cancer: A Preventable Disease       » One More Piece in the Puzzle of Liver Cancer Identified       » Smoking While Pregnant May Compromise Children's Kidney Function       » You Are What You Exhale      
INSIDE INDUSTRY
Eurofins Panlabs strengthens drug discovery services with GE Healthcares Cytiva. Cardiomyocytes

Eurofins Scientific specializing in food, environment and pharmaceutical products testing, has signed an agreement with GE Healthcare for the exclusive right to offer GE Healthcare's Cytiva™ Cardiomyocytes for drug discovery and early development cardio toxicity screening services.

The agreement allows Eurofins Panlabs to provide a unique offering for an early predictive measure of cardiac toxicity and function in a cost-effective and time-efficient manner compared to current expensive and time-consuming animal testing models. The initial range of cardiotoxicity screening services covered by the exclusive right will be expanded during the term of the agreement.

In drug development, up to three quarters of toxicity problems remain undetected until preclinical or later stages. Cardiotoxicity and hepatotoxicity are common causes of drug safety liabilities and withdrawal of drugs during development. The availability of more biologically relevant and predictive assays and cell models is key to helping improve the success rate and reducing the cost of the drug discovery and development process.

GE Healthcare is pioneering the development of human cell-based models such as Cytiva Cardiomyocytes, which provide a biologically relevant alternative to current cell models and primary cells for predictive cardiotoxicity testing.

Comments from Dr. Usha Warrior, Senior Director, Eurofins Panlabs: “This agreement gives us exclusivity in the CRO space to develop new assays for key indicators of cardiotoxicity using Cytiva cells for our clients. It also demonstrates our commitment to continuously develop the portfolio of services we offer to help clients systematically reduce the risk in the drug discovery  and development process.”

Eric Roman, General Manager of Research and Applied Markets, GE Healthcare Life Sciences, said: “The agreement with Eurofins Panlabs will help realize our vision of bringing the benefits of human cell-based assays and models to pharmaceutical and cell science research. Cardiotoxicity is a common cause of late-stage drug failure, so it's vital that developers have access to the right tools to help reduce this high attrition rate and to help increase patient safety.”

Click here for the complete issue.

NEWS CRUNCH  
news Philip Morris International and British American Tobacco receive award from PETA science group for AOP developments
news 6th Asia-Pacific Breast Cancer Summit to take place in Hong Kong
news MIT Hacking Medicine Robotics in Singapore!
PR NEWSWIRE  
Asia Pacific Biotech News
EDITORS' CHOICE  

Lady Ganga: Nilza'S Story
COLUMNS  
Subscribe to APBN E-Newsletter
Find us under 'Others' option to receive APBN e-newsletters thrice a month!

APBN Editorial Calendar 2017
January:
Healthcare Focus: LUNGS
February:
War on CANCER
March:
Traditional Chinese Medicines
April:
Diabetics Technology
May:
The Piece of Your Mind - Brain Health/Science
June:
Featuring Biotech Start-Ups/Companies
July:
Food Science & Technology
August:
Eye Care/ Eye Health
September:
No. 1 Killer - Heart Diseases, Diagnosis and Treatment
October:
Skin Diseases/Allergic Reactions
November:
Diseases threatening our Children
December:
Liver Health & Treatment/Technology
Editorial calendar is subjected to changes.
– Editor: Carmen, Jia Wen Loh
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Carmen
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   biotech_ad@wspc.com
Copyright© 2017 World Scientific Publishing Co Pte Ltd  •  Privacy Policy